<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843527</url>
  </required_header>
  <id_info>
    <org_study_id>ADC-US-RES-19185</org_study_id>
    <nct_id>NCT04843527</nct_id>
  </id_info>
  <brief_title>Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes</brief_title>
  <official_title>Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Diabetes Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, prospective, non-significant risk study to compare the impact of&#xD;
      the FreeStyle Libre Flash Glucose Monitoring System with and without a food logging&#xD;
      smartphone application on reducing time above 180 mg/dL in subjects with type 2 diabetes who&#xD;
      are not adequately controlled on their existing oral anti-diabetes medication regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 200 subjects will be enrolled to obtain at least 84 randomized&#xD;
      subjects,approximately 42 subjects per arm. Subjects will be randomized to use either the&#xD;
      FreeStyle Libre Flash Glucose Monitoring System or FreeStyle Libre Flash Glucose Monitoring&#xD;
      System with a food logging smartphone application to manage their diabetes.&#xD;
&#xD;
      The subsequent impact on reducing the amount of time spent above 180 mg/dL will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact on time above 180 mg/dL</measure>
    <time_frame>Three (3) months</time_frame>
    <description>To assess the impact of the FreeStyle Libre Flash Glucose Monitoring System with and with food logging app on time above 180 mg/dL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>FreeStyle Libre</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FreeStyle Libre plus food logging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Libre System</intervention_name>
    <description>FreeStyle Libre Flash Glucose Monitoring System</description>
    <arm_group_label>FreeStyle Libre</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Libre System plus food app</intervention_name>
    <description>FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application</description>
    <arm_group_label>FreeStyle Libre plus food logging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be at least 18 years of age.&#xD;
&#xD;
          -  Subject has been diagnosed with type 2 diabetes.&#xD;
&#xD;
          -  HbA1c greater than or equal to 7.5% and less than or equal to 9.5%&#xD;
&#xD;
          -  Subject is on 1 or 2 diabetes medications in the classes of metformin, SGLT-2&#xD;
             inhibitors, GLP-1 agonists and DPP-4 inhibitors.&#xD;
&#xD;
          -  Subject owns a compatible smartphone&#xD;
&#xD;
          -  Subject agrees to a 3-month period of no diabetes medication changes.&#xD;
&#xD;
          -  Subject is willing to make diet and lifestyle changes in response to education and&#xD;
             glucose data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently on insulin therapy or sulfonylurea-based medications.&#xD;
&#xD;
          -  Subject has known allergy to medical grade adhesive or isopropyl alcohol used to&#xD;
             disinfect skin.&#xD;
&#xD;
          -  Subject is known to be pregnant at the time of study enrollment (applicable to female&#xD;
             subjects only).&#xD;
&#xD;
          -  Subject has extensive skin changes/diseases at the proposed application sites that&#xD;
             could interfere with device placement or the accuracy of interstitial glucose&#xD;
             measurements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shridhara A Karinka, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Diabetes Care, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HealthPartners Institute dba International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Martens, MD</last_name>
      <phone>952-993-4865</phone>
      <email>Thomas.martens@parknicollet.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

